Form 4 for RNA Atrium Therapeutics, Inc.
Accepted 2026-09-22 16:20:33 ET · period of report 2026-09-18 · accession 0001193125-26-397955 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-22 16:20 | 2026-09-18 | RNA | Flanagan W. Michael | Dir | F - Tax | $8.95 | -22.8K | 32.0K | -42% | -$204.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-18 | F | D | 22,812 | $8.95 | 31,974 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |